We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influenza Management With Polyherbal Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03365336
Recruitment Status : Recruiting
First Posted : December 7, 2017
Last Update Posted : December 27, 2017
Sponsor:
Information provided by (Responsible Party):

December 2, 2017
December 7, 2017
December 27, 2017
January 1, 2018
March 15, 2018   (Final data collection date for primary outcome measure)
Time to improvement of symptoms [ Time Frame: Day 1 pretreatment upto Day 7 ]
Time to improvement of symptoms is defined as the time from initiation of study treatment to improvement of influenza symptoms for a duration of at least 21.5 hours (24 hours - 10%).
Same as current
Complete list of historical versions of study NCT03365336 on ClinicalTrials.gov Archive Site
  • Percentage change in participants positive for influenza virus titer and viral RNA at end of treatment [ Time Frame: 7 days ]
    Defined as the percentage of patients whose virus titer and ribonucleic acid (RNA) load are become less than the lower limit of quantification among those assessed for virus titer and RNA load. RNA load is measured by reverse transcription polymerase chain reaction (RT-PCR).
  • Time to alleviation of symptoms [ Time Frame: Day 1 pretreatment up to Day 7 ]
    Time to alleviation of symptoms is defined as the time between the initiation of the study treatment and the alleviation of influenza symptoms. The alleviation of influenza symptoms is defined as the time when all of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) have been assessed by the patient.
  • Time to improvement in the 4 systemic symptoms [ Time Frame: Day 1 pretreatment up to Day 7 ]
    Defined as the time between the initiation of the study treatment and the improvement in the 4 systemic symptoms symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue).
  • Time to improvement in the 3 respiratory symptoms [ Time Frame: Day 1 pretreatment up to Day 7 ]
    Defined as the time between the initiation of the study treatment and the improvement in the 3 respiratory symptoms (cough, sore throat, and nasal congestion).
  • Time to resolution of fever [ Time Frame: Day 1 pretreatment up to Day 7 ]

    Defined as the time between the initiation of the study treatment and the resolution of fever.

    The resolution of fever is defined as the time when the patient's self-measured temperature becomes less than 37º C.

  • Percentage of participants with adverse events [ Time Frame: Baseline up to Day 7 ]
  • Percentage of participants who had been hospitalized [ Time Frame: Baseline up to Day 7 ]
  • Percentage of participants with influenza-related complications [ Time Frame: Baseline up to Day 7 ]
    Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.
Same as current
Not Provided
Not Provided
 
Influenza Management With Polyherbal Formulation
Indian Herbal Medicine for Influenza - Randomized Controlled Study
The aim of this study is to determine the efficacy of Flu care polyherbal formulation in the management of acute uncomplicated case of Influenza within 48 hours of symptoms onset.
Influenza is one of the most common epidemics occurring in India during winter months. Most of the commonly used antiviral have limited efficacy and safety in influenza treatment. Flu Care polyherbal consist of antiviral, antitussive and anti-inflammatory herbal medicine. If this Flu care intervention is shown to be effective, there will be major potential benefits to general population.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Parallel follow up of two groups randomly allocated through a central randomization process.
Masking: None (Open Label)
Masking Description:
Open label study
Primary Purpose: Treatment
Influenza
  • Drug: polyherbal formulation
    Each Flu Care consist of 350 mg of polyherbal component
    Other Name: Flu Care
  • Drug: Oseltamivir 75mg
    All the participant has to take 75 mg of oseltamivir for five days.
  • Experimental: Intervention Group
    Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.
    Interventions:
    • Drug: polyherbal formulation
    • Drug: Oseltamivir 75mg
  • Active Comparator: Standard Care Group
    Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
    Intervention: Drug: Oseltamivir 75mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
April 15, 2018
March 15, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects above the age of 18 years, providing written informed consent.
  • Patients with a duration of influenza symptoms confirmed by all of the following:

    1. Fever ≥ 38º C (axillary) during the predose examinations or within the 4 hours prior if antipyretics were taken
    2. At least 1 each of the following general and respiratory symptoms associated with influenza is present with a severity of moderate or greater: i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion) Rapid diagnostic test, PCR, or viral culture positive for influenza in the 96 hours prior to first dose
  • The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:

    1. Time of the first increase in body temperature (an increase of at least 1º C from normal body temperature)
    2. Time when the patient experiences at least 1 new general or respiratory symptom

Exclusion Criteria:

Patients will be considered at high risk of influenza complications due to the presence of at least 1 of the following inclusion criteria:

  1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
  2. Endocrine disorders (including diabetes mellitus)
  3. Residents of long-term care facilities (e.g., nursing homes)
  4. Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus (HIV) infection with a cluster of differentiation 4 count > 350 cells/mm³ within the last 6 months)
  5. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, e.g., cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury)
  6. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
  7. Adults aged ≥ 65 years
  8. Blood disorders (such as sickle cell disease)
  9. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
  10. Morbid obesity (body mass index ≥ 40)

Other Exclusion criteria Any one of the following

  • Influenza vaccination with live attenuated vaccine in the 3 months prior to randomization
  • Antiviral treatment for influenza in 2 weeks prior to randomization
  • Severe Hepatic and renal impairment
  • Pregnant, attempting to conceive, or lactating women
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Alben Sigamani, MD 8884431444 alben.sigamani.dr@nhhospitals.org
Contact: Sanjaya Chauhan, Pharm.D 9611252350 drsanjayachauhan49@gmail.com
India
 
 
NCT03365336
OI-008-2017
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Organic India
Organic India
Not Provided
Principal Investigator: Dayanand B Yaligar, MBBS Narayana Hrudayalaya Hospital
Organic India
December 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP